| TMO |
Report |
Adjusted EPS |
BEAT |
pred ~$5.82 vs. cons $5.74 |
MEDIUM |
| TMO |
Report |
Revenue |
IN-LINE |
pred ~$11.60B vs. cons $11.58B |
MEDIUM |
| TMO |
Report |
Organic revenue growth |
IN-LINE |
pred ~3.2% vs. cons 3.0% |
MEDIUM |
| TMO |
Guide |
FY2026 adjusted EPS guidance |
UNCHANGED |
guide ~$24.88 midpoint vs. cons $24.94 (FY2026) |
MEDIUM |
| TMO |
Guide |
FY2026 revenue guidance |
UNCHANGED |
guide ~$47.70B midpoint vs. cons $47.73B (FY2026) |
MEDIUM |
| TMO |
Guide |
FY2026 organic revenue growth guidance |
UNCHANGED |
guide ~3.5% midpoint vs. cons 3.4% (FY2026) |
MEDIUM |
| TMO |
Guide |
FY2026 adjusted operating-margin expansion |
UNCHANGED |
guide ~70 bps vs. cons 70 bps (FY2026) |
LOW |
| TMO |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.5% |
— |
MEDIUM |
| TMO |
Return |
5-day cumulative residual |
+1.5% (FADE) |
A ~$0.08 EPS beat versus $5.74 consensus and ~3.2% organic growth versus 3.0% should support an initial positive reaction, but a largely unchanged FY2026 EPS midpoint of ~$24.88 versus $24.94 consensus leaves modest implicit out-period pressure and limits estimate-revision follow-through. |
MEDIUM |